Apotex Pharmachem Inc.

Brantford Chemicals Inc.

Other

Bhaskar Reddy Guntoori

Daqing Che

Yajun Zhao

Zhi-Xian Wang

Fan Wang

Stephen E Horne

K S Keshava Murthy

Gamini Weeratunga

Sammy Chris Duncan

Aaron C Kinsman

Jody Faught

Alan Chow

Mohammed Abdul Raheem

Kiran Kumar Kothakonda

Alfredo Paul Ceccarelli

Nageib Mohamed

Eckardt C G Wolf

Allan W Rey

Carlos Zetina-Rocha

K S Murthy

Elena Bejan

Uma Kotipalli

Murali Kondamreddy

Minh T N Nguyen

Ks Keshava Murthy

Svetoslav S Bratovanov

Laura Kaye Montemayor

Mohamed Ibrahim Zaki

Kaarina K Milnes

Kevin Wade Kells

Jodi Faught

Tianhao Zhou

Yuan Qiang Li

Joseph DiMartino

Yuanqiang Li

Nadia Corelli-Rennie

There is provided processes for preparing Lubiprostone and intermediates thereof. Also provided are compounds, including intermediates for preparing Lubiprostone as well compositions comprising Lubiprostone and other compounds, including intermediates for preparing Lubiprostone and other compounds. (I) 

Methods of making lubiprostone and intermediates thereof

A process provided for the preparation of the (S)- and (R)- alpha- ethyl-2-oxo-1-pyrrolidineacetamide of formula:(1) from (RS)-alpha-ethyl-2-oxo-1-pyrrolidineacetic acid of formula:(2) comprising: i) combining the (RS)-2 with a chiral base (resolving agent) in a resolution solvent and crystallizing from the said mixture the diastereomeric salt of (S)- or (R)-2 and chiral base; ii) regenerating (S)- or (R)-2 from the crystallized diastereomeric salt by treating with a suitable acid or acidic ion-exchange resin; iii) optionally regenerating (R)- or (S)-2 or their mixture (predominantly one enantiomer) from the crystallization mother liquor by treating with a suitable acid or acidic ion-exchange resin; iv) optionally epimerizing (RS)-2 by treating (R)- or (S)-2 or their mixture (predominantly one enantiomer) of step iii with an acid anhydride; V) optionally converting (RS)-2 of step iv into enantiomerically enriched (S)- or (R)-2 through steps i and ii; vi) formation of the mixed anhydride by reacting (R)- or (S)-2 with an alkyl or aryl sulfonyl halogen compound RSO2X in the presence of a suitable base; and vii) reacting the mixed anhydride with ammonia; wherein R represents C 1 to C 15 alkyl or aryl groups such as methyl, ethyl, p-toluenyl, 2,4,6-trimethylbenzyl, 2,4,6-trichloribenzyl, and X represents a halogen atom such as F, Cl and Br atoms. 

[object Object]

There is provided a process for the preparation of olanzapine comprising:

Processes for the synthesis of olanzapine

A process for the preparation and purification of Eplerenone is described wherein hydroxylated impurities are removed using a novel derivatization procedure.

Process for the preparation and purification of eplerenone

A process is provided for preparing (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 comprising:    

Process for the preparation of atorvastatin and intermediates

A process is provided for preparing pharmaceutical grade atorvastatin hemicalcium salt comprising:  

Process for producing atorvastatin hemicalcium

The present invention relates to a process for producing 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones of formula 1, including Finasteride and Dutasteride.

Process for the preparation of 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones

Provided is an efficient method for the preparation of 3-aryloxy-3-arylpropylamines, their optical stereoisomers, and pharmaceutically acceptable salts thereof. The process allows for the isolation of 3-aryloxy-3-arylpropylamines in high yield and purity. The present invention further relates to a process for producing fluoxetine, tomoxetine, norfluoxetine, duloxetine, nisoxetine, and their optically enriched (R)- and (S)-enantiomers.

Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers

A process for preparing torsemide or salts thereof comprising:

Process for the preparation of torsemide and related intermediates

The present invention provides a novel and improved process for the preparation of Zonisamide and the intermediates thereof. In one aspect of the present invention, the process provides for: the preparation and isolation of a novel crystalline form of anhydrous 1,2-benzisoxazole-3-methanesulfonic acid of formula 1; the direct chlorination of the acid of formula 1 into its acid chloride of formula 2; and the in situ conversion of the intermediate acid chloride of formula 2 into Zonisamide 

Process for the preparation of zonisamide and the intermediates thereof

A process for the preparation of the boron difluoride chelate of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolone carboxylic acid via:

Process for the preparation of the boron difluoride chelate of quinolone-3-carboxylic acid

A process for the preparation of Balsalazide and its pharmaceutically acceptable salts wherein the reaction comprises:

Safe process for the preparation of balsalazide

Process for the preparation of Flecainide, its pharmaceutically acceptable salts and important intermediates thereof that involves the use of the 2-halobenzoic acid and its derivatives as a starting material. The use of this process also allows for the synthesis of a novel intermediate useful in the production of Flecainide. This new process is an inexpensive and efficient process for the manufacture of these compounds.

Process for the preparation of Flecainide, its pharmaceutically acceptable salts and important intermediates thereof

A process for preparing (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, tert-butylester comprising:

Growing community of inventors

Brantford, Canada

Bhaskar Reddy Guntoori